Cited by 654Blood Pressure and Hypertension StudiesRenin-Angiotensin System StudiesHormonal Regulation and Hypertension

The DOI matches its Crossref record; 251 of the 251 references it cites were found in a registry or an index; 17 of the 282 sources its claims cite were checked for support.

Obesity, kidney dysfunction and hypertension: mechanistic links

Open access
Hall, John E., do Carmo, Jussara M., da Silva, Alexandre A., Wang, Zhen, Hall, Michael E.·2019·Nature Reviews Nephrology

Abstract

Excessive adiposity raises blood pressure and accounts for 65–75% of primary hypertension, which is a major driver of cardiovascular and kidney diseases. In obesity, abnormal kidney function and associated increases in tubular sodium reabsorption initiate hypertension, which is often mild before the development of target organ injury. Factors that contribute to increased sodium reabsorption in obesity include kidney compression by visceral, perirenal and renal sinus fat; increased renal sympathetic nerve activity (RSNA); increased levels of anti-natriuretic hormones, such as angiotensin II and aldosterone; and adipokines, particularly leptin. The renal and neurohormonal pathways of obesity and hypertension are intertwined. For example, leptin increases RSNA by stimulating the central nervous system proopiomelanocortin–melanocortin 4 receptor pathway, and kidney compression and RSNA contribute to renin–angiotensin–aldosterone system activation. Glucocorticoids and/or oxidative stress may also contribute to mineralocorticoid receptor activation in obesity. Prolonged obesity and progressive renal injury often lead to the development of treatment-resistant hypertension. Patient management therefore often requires multiple antihypertensive drugs and concurrent treatment of dyslipidaemia, insulin resistance, diabetes and inflammation. If more effective strategies for the prevention and control of obesity are not developed, cardiorenal, metabolic and other obesity-associated diseases could overwhelm health-care systems in the future.Hypertension is one of the most common comorbid conditions that is associated with obesity. Here, the authors discuss the complex interactions between renal, hormonal and nervous system factors that link excess adiposity with elevated blood pressure.Key pointsObesity is associated with chronic diseases, including hypertension, which is a major risk factor for chronic kidney disease and cardiovascular diseases such as stroke, myocardial infarction and heart failure.Excessive weight gain, especially when associated with visceral obesity, raises blood pressure and is the most important known risk factor for primary (essential) hypertension.Abnormal kidney function, which is associated with increased tubular sodium reabsorption, has a key role in initiating obesity-associated hypertension.Mechanisms that initiate obesity-induced sodium retention include kidney compression by visceral, perirenal and renal sinus fat, stimulation of the renin–angiotensin–aldosterone system, aldosterone-independent mineralocorticoid receptor activation and activation of the sympathetic nervous system.Sympathetic activation in obesity may be mediated by hypoxia, chemoreceptor activation, baroreflex dysfunction and adipokines, including leptin, which activates the central nervous system melanocortin pathway.Chronic obesity may gradually amplify hypertension, resulting in resistance to antihypertensive treatment and initiating a pathophysiological cascade of factors that exacerbate target organ injury.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

This review argues that excess adiposity, particularly visceral and perirenal/renal sinus fat, initiates primary hypertension through increased renal tubular sodium reabsorption driven by kidney compression, renin–angiotensin–aldosterone system (RAAS) and mineralocorticoid receptor (MR) activation, and increased renal sympathetic nerve activity (RSNA). It synthesizes human epidemiological and clinical trial data with experimental animal models to map the neurohormonal and renal pathways linking obesity to treatment-resistant hypertension and cardiorenal disease.

Key findings

  • Excessive adiposity accounts for 65–75% of primary (essential) hypertension, and at least 72% of patients with end-stage renal disease have hypertension and/or type 2 diabetes, both largely obesity-driven.
  • In the Framingham Heart Study (2,923 participants), high renal sinus fat conveyed a 2.2-fold increased risk of hypertension and a 2.3-fold increased risk of chronic kidney disease after adjusting for visceral adipose tissue and BMI; in the Dallas Heart Study, increased visceral (but not total or subcutaneous) adiposity was strongly associated with incident hypertension over a median 7-year follow-up.
  • MR antagonism (eplerenone) in high-fat-fed obese dogs blunted sodium retention, glomerular hyperfiltration and hypertension development by >50%; in humans, spironolactone reduced BP and urinary albumin excretion even on ACE inhibitors, and the PATHWAY-2 trial established spironolactone's efficacy in resistant hypertension.
  • Renal denervation nearly normalized BP in dogs with established obesity-induced hypertension; in overweight/obese patients with resistant hypertension, catheter-based radiofrequency RDN lowered office BP by −25 to −30/−10 to −12 mmHg for up to 24 months, though SYMPLICITY HTN-3 failed to show superiority over sham.
  • Leptin links adiposity to RSNA via the CNS POMC–MC4R pathway; individuals with MC4R deficiency had lower hypertension prevalence and reduced noradrenaline excretion despite severe obesity, while MC4R agonists raise BP and HR despite weight loss.

Methods

  • Narrative review synthesizing mechanistic, epidemiological and clinical evidence on obesity-induced hypertension, kidney dysfunction and cardiometabolic risk.
  • Draws on human cohort studies (Framingham Heart Study, Dallas Heart Study, Nurses' Health Study, Health Professionals Follow-up Study, Johns Hopkins Precursors Study, Atherosclerosis Risk in Communities study), randomized trials (PATHWAY-2, SYMPLICITY HTN trials, RADIANCE-HTN SOLO, SPYRAL HTN-ON MED), and experimental animal models (high-fat-fed dogs, rabbits, rodents; genetic models such as ob/ob, db/db mice and Zucker rats).
  • No primary data collection or meta-analysis; evidence is organized thematically around renal compression, RAAS/MR activation, natriuretic peptide deficiency, gut hormones/microbiota, adipokines, and sympathetic nervous system mechanisms.

Limitations

  • The paper notes that mechanisms of obesity-induced hypertension "have not been fully elucidated," that genetic/epigenetic contributions explain "only a tiny fraction" of hypertension, and that the importance of leptin-induced aldosterone secretion in humans and male rodents "is still unclear."
  • It states that rodent models do not show fat adherence to the renal capsule or kidney compression as in obese dogs, rabbits and humans, limiting translation; and that many genetic obesity models have deranged adipokine or POMC–melanocortin signalling.
  • It notes that no large randomized trials have compared RAAS blockers with other antihypertensives in lean versus obese patients, that RDN trials were confounded by unverified ablation extent and concurrent medications, and that evidence for a causal role of gut microbiota/metabolites in obesity-induced hypertension is limited.
  • Evident from the text: as a narrative review without systematic search or quantitative synthesis, it is susceptible to selection and interpretation bias; several cited findings rest on small samples (e.g., four leptin-deficient patients) or animal models.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41581-019-0145-4

Cites

251 of 251 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

200 Not checked yet · 51 Own interpretation · 14 No basis given · 8 Partly supported · 2 Supported · 2 Own method · accuracy not yet measured

Verify all 265 references — free account

Show all 166 claims

  • It may state two separate claims as one. 106
  • Probably not a substantial claim. 8
  • The quote only partly states this claim. 1
111 of 111
  • The paper relies on this without support.

    Obesity causes only modest increases in angiotensin II formation.

    “Although obesity causes only modest increases in AngII formation, pharmacological RAAS blockade blunts sodium retention and hypertension in obesity6.”
  • The paper relies on this without support.

    Renal sodium reabsorption is stimulated by low levels of angiotensin II acting via direct effects on several NaCl transporters and by inducing constriction of efferent arterioles.

    “Renal sodium reabsorption is stimulated by low levels of AngII that act via direct effects on several NaCl transporters and by inducing constriction of efferent arterioles.”
  • The paper relies on this without support.

    11βHSD2 colocalizes with the mineralocorticoid receptor in the collecting tubules and converts cortisol to cortisone, which is relatively inert at the mineralocorticoid receptor.

    “11βHSD2 colocalizes with MR in the collecting tubules and converts cortisol, which has a high affinity for the MR, to cortisone, which is relatively inert at the MR.”
  • The paper relies on this without support.

    Renal denervation removes both sympathetic efferent and sensory afferent renal nerves.

    “RDN removes both sympathetic efferent and sensory afferent renal nerves.”
  • The paper relies on this without support.

    Increased stimulation of renal sympathetic efferent nerves increases renin secretion, renal tubular sodium reabsorption and blood pressure.

    “Increased stimulation of renal sympathetic efferent nerves is recognized to increase renin secretion, renal tubular sodium reabsorption and BP.”
  • The paper relies on this without support.

    Hypoxaemia may occur in obesity without obstructive sleep apnoea.

    “Hypoxaemia may also occur in obesity without OSA.”
  • The paper relies on this without support.

    Obesity-induced hypertension often occurs in the absence of obstructive sleep apnoea.

    “Although obesity-induced hypertension often occurs in the absence of OSA, the severity of hypertension is exacerbated when OSA coexists with obesity183,185.”
7 of 7

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 251 references

Cited by

Sorted by citations

Metadata

Authors
Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E.
Affiliations
University of Mississippi Medical Center (US)
Corresponding author
Hall, John E.
Venue
Nature Reviews Nephrology
Published
2019-04-23
Volume
15
Issue
6
Pages
367-385
ISSN
  • 1745-8323 (ISSN-L)
  • 1759-5061
  • 1759-507X
OpenAlex
W2942253286
Cited by
654
References
251
Citations by year
2026: 88 · 2025: 101 · 2024: 93 · 2023: 104 · 2022: 88 · 2021: 98 · 2020: 64 · 2019: 15
FWCI
12.01
Type
journal article
Language
en
Open access
Locations
  • Nature Reviews Nephrology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Heart, Lung, and Blood Institute (P01HL051971)
  • National Institute of General Medical Sciences (P20GM104357, U54GM115428)
  • National Institute of Diabetes and Digestive and Kidney Diseases (F32DK009941, K08DK099415)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Keywords
obesity, hypertension, renal dysfunction, renal sodium reabsorption, renal sympathetic nerve activity, leptin, angiotensin II, aldosterone, renin-angiotensin-aldosterone system, adipokines, visceral fat, mineralocorticoid receptor, glucocorticoids, oxidative stress, treatment-resistant hypertension, cardiorenal disease, obesity-related comorbidities
MeSH terms
Aldosterone, Angiotensin II, Humans, Hypertension, Kidney, Kidney Tubules, Obesity, Pro-Opiomelanocortin, Renin, Sodium, Sympathetic Nervous System, Receptors, Mineralocorticoid, Oxidative Stress, Leptin, Receptor, Melanocortin, Type 4, Adipokines, Renal Reabsorption

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review